DSM buys Pentapharm
This article was originally published in The Tan Sheet
DSM announces Aug. 29 the closing of its deal to buy 100% of Pentapharm Holding's shares, saying it "fits well" with the firm's 2010 strategy to "focus on accelerating and innovative growth." The firm says the official closing represents the "the first major milestone in the joint future and officially starts the cooperative integration activities." DSM does not expect any immediate changes for any of the internal or external stakeholders and all Pentapharm contact persons will remain the same for the time being, the firm states...
You may also be interested in...
Health technology assessment body NICE has now recommended that selective internal radiation therapy can be used on England’s National Health Service for treating advanced liver cancer.
A “structured dialog” led by the European Commission with pharmaceutical industry stakeholders provides a critical opportunity to address weaknesses in the stability and security of the supply chain by improving the environment for local manufacturing, Medicines for Europe believes.
Despite a slight increase in revenue, South Africa’s Adcock continues to struggle as it reports a continued drop in gross profit. The company expects the economy to remained constrained due to COVID-19, but is eagerly anticipating recovery with the government’s vaccine roll-out.